+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies

Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair (omalizumab) for…

read more

Nityr ( nitisinone ), generic of Orfadin, approved in EU for the treatment of hereditary tyrosinaemia type 1 (HT-1)

Nityr is a medicine used to treat hereditary tyrosinaemia type 1 (HT-1). This is a rare disease in which the body…

read more

FDA approves Poteligeo (mogamulizumab-kpkc), for the treatment of two rare types of non-Hodgkin lymphoma

The U.S. Food and Drug Administration has approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients…

read more

Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy

Myalepta is a medicine used in addition to diet to treat lipodystrophy, where patients have loss of fatty tissue under…

read more

Accord Healthcare’s Pelgraz (pegfilgrastim) Given Green Light by CHMP

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Accord's Pelgraz (pegfilgrastim), pegylated granulocyte-colony stimulating…

read more

Pfizer’s Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.

Pfizer has announced the European Commission (EC) has approved TRAZIMERA,  a biosimilar to Herceptin  (trastuzumab), for the treatment of human epidermal…

read more

Onpattro (patisiran), a new drug that addresses unmet medical need for treatment of hereditary transthyretin amyloidosis

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Onpattro (patisiran), for the…

read more

AbbVie Receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

AbbVie , a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., announced that the U.S. Food and Drug…

read more

FDA approves Tibsovo (ivosidebib), first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

The U.S. Food and Drug Administration has approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or…

read more

Janssen Announces U.S. FDA Approval of SYMTUZA, the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved…

read more

Third Novartis Phase III trial shows Kisqali (ribociclib) combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3…

read more

FDA approves TPOXX (tecovirimat) the first drug with an indication for treatment of smallpox

The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.…

read more

CONTACT US

ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message

captcha